Shoshana M Rosenberg1, Shari Gelber2, Richard D Gelber2, Ethan Krop1, Larissa A Korde3, Olivia Pagani4, Ann H Partridge1. 1. 1 Dana-Farber Cancer Institute , Department of Medical Oncology, Boston, Massachusetts. 2. 2 Dana-Farber Cancer Institute , Department of Biostatistics and Computational Biology, Boston, Massachusetts. 3. 3 Division of Medical Oncology, University of Washington , Seattle, Washington. 4. 4 Institute of Oncology and Breast Unit of Southern Switzerland , Bellinzona, Switzerland .
Abstract
PURPOSE: POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer) is a prospective clinical trial assessing safety and pregnancy outcomes in premenopausal hormone receptor-positive breast cancer survivors (age ≤42) who interrupt endocrine therapy (ET) to attempt pregnancy. We sought to assess interest in this study and perspectives on fertility preservation (FP) among United States medical oncologists who had previously enrolled women at their institutions on select premenopausal endocrine studies. METHODS: From August 2015 to December 2015, 301 investigators were invited to complete a web-based survey on behalf of their institution. We assessed FP practices and attitudes, barriers to discussing FP, and willingness to open/enroll women on POSITIVE. RESULTS: Of 93 respondents (31%), most were affiliated with an National Cancer Institute (NCI)-designated comprehensive cancer center (44%). Almost all said they usually or always discussed the issue of future fertility with patients (98%) and referred patients with fertility questions to specialists (97%). Over half of respondents cited discomfort with recommending women to stop ET, as well as perceived patient concern regarding ET interruption, as factors seen as influencing POSITIVE enrollment; however, 84% were willing to recommend trial participation for selected patients. CONCLUSIONS: Most providers reported discussing fertility with their young patients, indicating awareness of FP guidelines for cancer patients. While most oncologists said that they would be willing to recommend POSITIVE, many also expressed discomfort in endorsing women to stop ET temporarily, underscoring the need for prospective data regarding the safety of ET interruption. High willingness to recommend POSITIVE suggests the potential for successful accrual to this study, which addresses a critical issue for young breast cancer survivors.
PURPOSE: POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer) is a prospective clinical trial assessing safety and pregnancy outcomes in premenopausal hormone receptor-positive breast cancer survivors (age ≤42) who interrupt endocrine therapy (ET) to attempt pregnancy. We sought to assess interest in this study and perspectives on fertility preservation (FP) among United States medical oncologists who had previously enrolled women at their institutions on select premenopausal endocrine studies. METHODS: From August 2015 to December 2015, 301 investigators were invited to complete a web-based survey on behalf of their institution. We assessed FP practices and attitudes, barriers to discussing FP, and willingness to open/enroll women on POSITIVE. RESULTS: Of 93 respondents (31%), most were affiliated with an National Cancer Institute (NCI)-designated comprehensive cancer center (44%). Almost all said they usually or always discussed the issue of future fertility with patients (98%) and referred patients with fertility questions to specialists (97%). Over half of respondents cited discomfort with recommending women to stop ET, as well as perceived patient concern regarding ET interruption, as factors seen as influencing POSITIVE enrollment; however, 84% were willing to recommend trial participation for selected patients. CONCLUSIONS: Most providers reported discussing fertility with their young patients, indicating awareness of FP guidelines for cancerpatients. While most oncologists said that they would be willing to recommend POSITIVE, many also expressed discomfort in endorsing women to stop ET temporarily, underscoring the need for prospective data regarding the safety of ET interruption. High willingness to recommend POSITIVE suggests the potential for successful accrual to this study, which addresses a critical issue for young breast cancer survivors.
Entities:
Keywords:
breast cancer; endocrine therapy; fertility; pregnancy
Authors: Joseph M Letourneau; Erin E Ebbel; Patricia P Katz; Audra Katz; Wei Z Ai; A Jo Chien; Michelle E Melisko; Marcelle I Cedars; Mitchell P Rosen Journal: Cancer Date: 2011-09-01 Impact factor: 6.860
Authors: Stephanie J Lee; Leslie R Schover; Ann H Partridge; Pasquale Patrizio; W Hamish Wallace; Karen Hagerty; Lindsay N Beck; Lawrence V Brennan; Kutluk Oktay Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Alison W Loren; Pamela B Mangu; Lindsay Nohr Beck; Lawrence Brennan; Anthony J Magdalinski; Ann H Partridge; Gwendolyn Quinn; W Hamish Wallace; Kutluk Oktay Journal: J Clin Oncol Date: 2013-05-28 Impact factor: 44.544
Authors: Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis Journal: N Engl J Med Date: 2014-06-01 Impact factor: 91.245
Authors: Alejandra García; Gabriela Candás; Agustina Bemi; Héctor Daniel Vuoto; Ernesto Korbenfeld; Juan Isetta; Lucas Cogorno; Agustina González Zimmermann; Marcia Sigal; Santiago Acevedo; Julia Berwart; Martín Naveira; María Delfina Ocampo; Juan Luis Uriburu Journal: Ecancermedicalscience Date: 2021-02-10
Authors: John M Salsman; Betina Yanez; Mallory A Snyder; Alexis R Avina; Marla L Clayman; Kristin N Smith; Khouri Purnell; David Victorson Journal: Support Care Cancer Date: 2021-03-25 Impact factor: 3.359
Authors: Carlo Alviggi; Sandro C Esteves; Raoul Orvieto; Alessandro Conforti; Antonio La Marca; Robert Fischer; Claus Y Andersen; Klaus Bühler; Sesh K Sunkara; Nikolaos P Polyzos; Ida Strina; Luigi Carbone; Fabiola C Bento; Daniela Galliano; Hakan Yarali; Lan N Vuong; Michael Grynberg; Panagiotis Drakopoulos; Pedro Xavier; Joaquin Llacer; Fernando Neuspiller; Marcos Horton; Matheus Roque; Evangelos Papanikolaou; Manish Banker; Michael H Dahan; Shu Foong; Herman Tournaye; Christophe Blockeel; Alberto Vaiarelli; Peter Humaidan; Filippo M Ubaldi Journal: Reprod Biol Endocrinol Date: 2020-05-13 Impact factor: 5.211
Authors: Zhuoxin Sun; Samuel M Niman; Olivia Pagani; Ann H Partridge; Hatem A Azim; Fedro A Peccatori; Monica Ruggeri; Angelo Di Leo; Marco Colleoni; Richard D Gelber; Meredith M Regan Journal: Breast Date: 2020-06-02 Impact factor: 4.380